Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

January 15, 2006 (Vol. 26, No. 2)

Licensing & Collaborations for Tamiflu Patent

Threat of Avian Flu Pandemic Has Countries & Pharma Firms Exploring Manufacturing Options

  • If profits are the carrot, compulsory licensing is the stick in the unfolding drama to ensure adequate supplies of oseltamivir throughout the world in an attempt to mitigate an avian flu pandemic. In dire situations, you want to have march-in rights, says Vijay Samant, CEO of vaccine manufacturer Vical ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.